生物科技板块周一大涨：Silence 被 Merck KGaA 以 13 亿美元收购、SCWorx 签新合同、Disc Medicine 三期临床达标

Biotech and healthcare stocks surged on Monday, drawing investor attention to Silence Therapeutics' $1.3 billion acquisition deal, SCWorx's new healthcare agreement and Disc Medicine's positive Phase 3 trial results. The developments highlighted acquisition-driven upside, contract expansion and clinical progress as key catalysts behind the rally.
Read on.....
Silence Therapeutics plc (SLN)
Shares of Silence Therapeutics surged over 125% on Monday after Merck KGaA agreed to acquire the company in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion. Shareholders will receive $20 per American Depositary Share, representing a 130% premium to the October 16 closing price. The transaction is expected to close in the first quarter of 2027.
Currently, SLN is trading at $19.58, up 125.37%.
SCWorx Corp. (WORX)
Shares of SCWorx jumped over 105% after the healthcare data management company announced a new agreement with an independent, community-owned healthcare system serving New Mexico, Arizona, Colorado and Utah. Under the agreement, SCWorx will provide supply chain data management services to improve the accuracy and usability of healthcare product information. The deal expands its customer base and supports its strategy to grow recurring revenue.
Currently, WORX is trading at $2.58, up 107.70%.
Disc Medicine, Inc. (IRON)
Shares of Disc Medicine gained over 40% after its Phase 3 APOLLO trial of bitopertin met both co-primary endpoints in adults and adolescents with erythropoietic protoporphyria (EPP), including X-linked protoporphyria. The trial demonstrated a 41.4% reduction in whole-blood metal-free protoporphyrin IX versus placebo and a 12.2-hour increase in average monthly pain-free time in light during month six. Disc plans to resubmit its New Drug Application to the U.S. Food and Drug Administration by year-end 2026, with a regulatory decision anticipated by mid-2027.
Currently, IRON is trading at $78.82, up 38.67%.
Actinium Pharmaceuticals, Inc. (ATNM)
Shares of Actinium Pharmaceuticals rose over 16% after the company announced plans to present clinical and preclinical data on its investigational radiotherapy candidate ATNM-400 at the European Association of Nuclear Medicine Congress in Vienna, Austria. The clinical presentation will feature early data from an ongoing Phase 1 study in metastatic castration-resistant prostate cancer, while preclinical research will examine ATNM-400 in KRAS- and ALK-driven non-small cell lung cancer models. The candidate targets HER3 and remains investigational.
Currently, ATNM is trading at $1.31, up 15.86%.
Evaxion A/S (EVAX)
Evaxion reported three-year follow-up data showing durable clinical responses to its personalized cancer vaccine EVX-01 in patients with advanced melanoma. No tumor progression was reported among patients who remained in the trial's extension phase. The Phase 2 study previously reported a 75% objective response rate, including complete responses in 25% of patients. The company plans to present updated clinical and immune-response data at the ESMO Congress on October 24, 2026.
Currently, EVAX is trading at $3.29, up 16.25%.
This Day In History:
On this day in 1943, Rutgers University researcher Albert Schatz isolated streptomycin, an antibiotic that became a major breakthrough in the treatment of tuberculosis. Discovered through research on soil microorganisms, streptomycin helped transform the fight against one of the world's deadliest infectious diseases and opened new possibilities for antibiotic therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.